01 1Cipla
01 1DASATINIB (A)
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2021-03-22
Pay. Date : 2021-02-10
DMF Number : 35219
Submission : 2020-12-24
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is DASATINIB (A), with a corresponding US DMF Number 35219.
Remarkably, this DMF maintains an Active status since its submission on December 24, 2020, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 22, 2021, and payment made on February 10, 2021, indicating their dedication to facilitating drug approvals, Categorized as Type II
